White House Summit on Biotechnology and Biomanufacturing

Published on :

The White House Summit on
Biotechnology and Biomanufacturing will include three (3) sessions, where participants will exchange views on the opportunities for biotechnology and biomanufacturing to advance the American economy and U.S. global leadership in this critical technology.

5 Questions with Jason Bosiacki, Associate Director, Manufacturing Operations at NextCure

Published on :

Jason received his bachelor’s degree in biology with a minor in chemistry from Frostburg State University. He has been in the biotech industry for 12 years, having spent most of that time in R&D, primarily immunology and in the manufacturing of biologics, making monoclonal antibodies and fusions proteins.

The Role hMSCs Play in Bioengineering Solutions for Military Medicine

Published on :

Join us on Tuesday, June 14th at 11:00 AM EST for RoosterBio’s client-led seminar: The Role hMSCs Play in Bioengineering Solutions for Military Medicine. We will be joined by Lorena [….]

Clene Boosts Manufacturing, Hiring in Preparation of Potential Commercialization of ALS Add-On Treatment

Published on :

In December, the company received the benefit of a $1 million grant from the Maryland Department of Housing and Community Development to expand its manufacturing capacity in Elkton. The site is being added in order to increase Clene’s manufacturing capacity and support potential commercialization of its nanocrystal-based asset, CNM-Au8. Mark G. Mortenson, Clene’s Chief Scientific Officer, said the expansion of the company’s capacity in Elkton will provide them with forty-times their manufacturing capacity by 2025.

A Biomanufacturing Bottleneck Threatens To Blunt Biotech’s Boom

Published on :

At this moment, a confluence of factors, including the boom in mRNA vaccine technology and new cell and gene therapy firms, has grown beyond the capacity of the nation’s contract manufacturing industry, which firms depend on to outsource their therapy production or meet sudden demand. Life sciences startups need these spaces to run clinical trials and work out kinks in their own manufacturing processes before making bigger real estate commitments.
Contract manufacturing organizations are booked solid throughout the rest of the year, said Matt Gardner, a biomanufacturing specialist who was just named head of CBRE’s U.S. Advisory Life Sciences Practice. Finding small-batch production space in the 1,000-liter stainless steel tanks used to create and manufacture drugs or new biologics won’t be possible until 2023. 
“There’s nowhere near enough pilot-scale production, which is where companies fail fast and fail forward,” Gardner said. “You want to fail at 500 liters, so you don’t at 50,000 liters. That’s the scale where we see tremendous demand and need much more of.”